Identification of markers of prostate cancer progression using candidate gene expression

Larkin, Samantha; Holmes, Sharon; Cree, Ian A.; Walker, Tristan J.; Basketter, Vanessa; Bickers, Bridget; Harris, Scott; Garbis, Spiros D.; Townsend, Paul A.; Aukim-Hastie, Claire

doi:10.1038/bjc.2011.490

Cited by 89 publications

(71 citation statements)

References 58 publications

(71 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present report revealed that TRIP13 was highly expressed in CRC tumor tissues and various CRC cell lines. High expression of TRIP13 has also been reported in head and neck cancer, as well as in prostate cancer (20,28), indicating that TRIP13 may be overexpressed in a variety of cancers, similar to other kinetochore-localized proteins (25)(26)(27). Together with the current results, those studies suggest that TRIP13 is important in the progression of multiple cancers.…”

Section: Discussionsupporting

confidence: 77%

TRIP13 is expressed in colorectal cancer and promotes cancer cell invasion

et al. 2016

View full text Add to dashboard Cite

Abstract. Thyroid hormone receptor interactor 13 (TRIP13) is a member of the ATPases associated with various cellular activities family of proteins and is highly conserved in a wide range of species. Recent studies have demonstrated that TRIP13 is critical for the inactivation of the spindle assembly checkpoint and is associated with the progression of certain cancers. In the present study, the role of TRIP13 in colorectal cancer (CRC) was examined. Reverse transcription-quantitative polymerase chain reaction analysis revealed that TRIP13 messenger RNA was highly expressed in multiple CRC tissues. The depletion of TRIP13 in CRC cells suppressed cell proliferation, migration and invasion. To determine whether the catalytic activity of TRIP13 was critical for cancer progression, an inactive mutant of TRIP13 was expressed in CRC cells. The invasion of cancer cells that expressed the mutant TRIP13 was significantly reduced compared with that of the wild type TRIP13-expressing cancer cells. These results indicate that TRIP13 could be a potential target for CRC treatment. IntroductionThe ATPases associated with various cellular activities (AAA+) family of proteins comprises a functionally different group of enzymes that are involved in an array of cellular processes, including protein degradation, protein-complex disassembly and DNA replication (1). The AAA+ proteins are present in all kingdoms, and are characterized by the presence of conserved AAA+ domains that contain Walker A and Walker B motifs, followed by a conserved region called second region of homology (2). The majority of AAA+ proteins form hexamers to exert their biological functions. The chemical energy generated by adenosine triphosphate (ATP) hydrolysis by this family of proteins induces conformational changes in the substrate proteins to modulate their functions (3,4).A previous study reported that certain AAA+ enzymes are associated with tumor progression (5). For example, reptin [also known as RuvB-like (RUVBL) 2] and pontin (RUVBL1) have been demonstrated to be overexpressed in several tumors (5). These proteins interact with c-Myc or β-catenin, thus modulating their transcriptional activities to promote tumor progression (6). AAA+ proteins hydrolyze ATP, and thus, chemical inhibitors that disrupt the activities of cancer-associated AAA+ proteins may represent promising anti-cancer drugs.Thyroid hormone receptor interactor 13 (TRIP13, also known as 16E1BP and pachytene checkpoint 2) is a member of the AAA+ family proteins and is conserved in a wide range of species (7). It was first identified as a protein that interacts with human papilloma virus E1 proteins by a yeast two-hybrid analysis, but the physiological function of the interaction remains unknown (7). Accumulating studies have demonstrated that TRIP13 plays pivotal roles in meiotic recombination and DNA repair in plants, yeast, worms and mice (8-12). TRIP13 forms a stable hexameric ring, and ATP binding, as well as ATP hydrolysis, are critical for the function of the protein (13). Previous...

show abstract

Section: Discussionsupporting

confidence: 77%

TRIP13 is expressed in colorectal cancer and promotes cancer cell invasion

et al. 2016

View full text Add to dashboard Cite

show abstract

“…22 A study regarding a predictive biomarker model for advanced prostate cancer showed ANPEP was closely associated with prostate cancer metastasis, as a major oncogene involved in tumor cell metastasis. 23 HOXB8 expression is significantly downregulated in all colon cancer cell lines; and HOXB8 is believed to be associated with the occurrence of colon cancer.…”

Section: Discussionmentioning

confidence: 99%

Establishment of a Predictive Genetic Model for Estimating Chemotherapy Sensitivity of Colorectal Cancer with Synchronous Liver Metastasis

Pan

et al. 2013

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

Objective: We examined the whole genome expression profile in advanced colorectal cancer (ACC) patients who had received FOLFOX4 chemotherapy to establish a genetic biomarker model predicting chemotherapy sensitivity. Methods: Eligible ACC patients were divided into two groups, based on postchemotherapy evaluation results: specifically, the sensitive group (experimental group) and the resistant group (control group). The genome expression profiles of colorectal cancer tissues were examined using DNA microarray analysis, and differential gene expression was identified using a significance analysis of the microarray. The probe signal log ratios were used to produce the area-under-the-curve, sensitivity, and specificity for candidate genes. Genes exhibiting differential expression and significant predictive power were used to simulate a genetic model for estimating chemotherapy sensitivity. Results: Totally, 30 ACC patients were eligible for the study, 13 assigned to the experimental group and 17 to the control group. In total, 30 genes showing significant differential expression were identified. Seven candidate genes (NKX2-3, FXYD6, TGFB1I1, ACTG2, ANPEP, HOXB8, and KLK11), which exhibited positive or negative correlations, were incorporated into a genetic model, with an overall accurate predication rate of 93.3%. Conclusions: The predictive model involving the seven genes listed had high accuracy in estimating chemotherapy sensitivity to the FOLFOX4 regimen.

show abstract

“…Our results show that ANPEP was dramatically up-regulated in both the low metastatic and advanced melanoma cell lines. Other researchers validated the dysregulation of ANPEP as a risk factor for a particularly aggressive form of prostate cancer, suggesting an important role of ANPEP in cancers (Larkin et al, 2012).…”

Section: Discussionmentioning

confidence: 98%